相关实验视频
Updated: Jul 21, 2025

04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
509
针对肥胖的超级大片药物:脏病学家的第一课
Evan M Zeitler1, Kulveer Dabb2, Danial Nadeem2
1Division of Nephrology and Hypertension, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
概括
肥胖会增加慢性病 (CKD) 的风险和心血管问题. 新型烯疗法促进显著的体重减轻,并提供心血管保护,有利于CKD患者.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 全球肥胖率的上升增加了慢性疾病的风险,特别是影响功能和心血管健康.
- 肥胖是患慢性病 (CKD) 的重要危险因素,并使现有的心血管疾病恶化.
研究的目的:
- 审查肥胖和减肥对CKD的影响.
- 探索CKD患者因因克雷丁治疗的生物学基础和临床证据.
- 为科医生和患者提供关于肥胖治疗的实用处方建议.
主要方法:
- 关于肥胖对CKD和心血管结果的影响的文献综述.
- 分析支持基于英克雷丁的疗法的机制和临床数据.
- 综合当前的证据,为临床实践指南提供信息.
主要成果:
- 蓄意减肥显示出对慢性病中不良脏和心血管结果的保护作用.
- 新型的胰岛素药物疗法可以实现显著的减肥,相当于手术干预.
- 在临床研究中,因克雷丁疗法显示出一致的心血管保护益处.
结论:
- 胰岛素治疗代表了一种有前途的方法来管理CKD患者的肥胖症.
- 证据支持使用减肥干预措施,包括新型药物治疗,以改善CKD和心血管预后.
- 本综述为科医生和患者提供了关于CKD肥胖治疗的实际处方建议.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
Oral Hypoglycemic Agents: Glinides
188
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
188
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
206
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
206
Antihypertensive Drugs: Direct Renin Inhibitors
687
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
687
Antihypertensive Drugs: Types of β-Blockers
741
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
741
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
